> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CVM Moves to Rescind Phibro Animal’s Carbadox
- URL: https://www.fdaweb.com/cvm-moves-to-rescind-phibro-animals-carbadox/
- Published: 2016-04-08T12:00:00.000Z
- Updated: 2026-09-14T20:53:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135315

> CVM has begun an approval rescission action against Phibro Animal Health’s carbadox and its use in treating swine because the drug may leave trace amounts of a carcinogenic residue. The Center’s move comes after it recently reexamined the drug’s safety profile and conducted a preliminary risk characterization that indicated there could be potential risk to human health from ingesting pork, especially pork liver, derived from carbadox-treated pigs. FDA-approved alternative antibiotics are available to treat swine, the agency says.  
>  
> “The manufacturer of carbadox has failed to provide sufficient scientific data to demonstrate the safety of this drug given evidence that carbadox may result in carcinogenic residues,” an [agency release](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494934.htm?ref=fdaweb.com) says. “As a result, FDA’s Center for Veterinary Medicine is taking legal action to remove this product from the marketplace.”